Innovent Biologics’ GFH925 Earns Breakthrough Therapy Designation for KRASG12C CRC Treatment
The Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics’ (HKG: 1801) Category...
Innovent Biologics
Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting
China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...
Innovent Biologics Sees 6.7% Revenue Increase in 2022 Amidst R&D Growth and Product Expansion
Biopharmaceutical company Innovent Biologics Inc., (HKG: 1801), has reported revenues of RMB 4.55 billion (USD...
Innovent Biologics Begins Phase I Trial for IBI333 in Neovascular AMD
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first subject dosing in a Phase...
Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...
Innovent Biologics Posts Strong Q4 Revenues Amid COVID-19 Challenges
Innovent Biologics Inc. (HKG: 1801) announced product revenues of RMB 1 billion (USD 148.2 million)...
Innovent Biologics Doses First Patient in Phase III Study for Mazdutide
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
Legend Biotech’s Carvykti Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) website indicates that a market approval filing from Legend...
Innovent Biologics’ GFH925 Receives Breakthrough Therapy Designation
China’s Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics (HKG: 1801) has...
IASO Biotherapeutics Receives FDA Approval for CT103A IND Application
China-based IASO Biotherapeutics has announced approval from the US FDA for an Investigational New Drug...
Innovent Biologics Announces Strategic Partnerships to Form Tumor Diagnosis and Treatment Alliance
China-based Innovent Biologics (HKG: 1801) has announced a series of strategic partnerships with compatriot firms...
Innovent Biologics Collaborates with LG Chem for Tigulixostat in China
China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South...
ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...
Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022
China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...
Innovent Biologics Doses First Volunteer in Orismilast Phase I Study
China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...
Eli Lilly Ends License for Innovent’s Tyvyt Outside China
Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...
IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD
China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...